"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 3 | 0 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 2 | 6 |
| 2004 | 3 | 1 | 4 |
| 2005 | 4 | 3 | 7 |
| 2006 | 8 | 2 | 10 |
| 2007 | 7 | 2 | 9 |
| 2008 | 14 | 4 | 18 |
| 2009 | 19 | 9 | 28 |
| 2010 | 23 | 11 | 34 |
| 2011 | 31 | 9 | 40 |
| 2012 | 38 | 12 | 50 |
| 2013 | 31 | 9 | 40 |
| 2014 | 39 | 5 | 44 |
| 2015 | 21 | 8 | 29 |
| 2016 | 36 | 8 | 44 |
| 2017 | 27 | 15 | 42 |
| 2018 | 40 | 12 | 52 |
| 2019 | 32 | 9 | 41 |
| 2020 | 51 | 17 | 68 |
| 2021 | 54 | 9 | 63 |
| 2022 | 44 | 0 | 44 |
| 2023 | 42 | 0 | 42 |
| 2024 | 26 | 22 | 48 |
| 2025 | 9 | 2 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Longitudinal Changes in Tenofovir and Tenofovir Diphosphate Concentrations Among Pregnant Women Using Oral PrEP for HIV Prevention: Findings From Durban, South Africa. J Acquir Immune Defic Syndr. 2025 Apr 01; 98(4):357-362.
-
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection. Curr Opin HIV AIDS. 2025 May 01; 20(3):249-256.
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
-
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial. Lancet HIV. 2025 Mar; 12(3):e180-e190.
-
Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
-
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study. Lancet HIV. 2025 Feb; 12(2):e130-e142.
-
Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment. J Int AIDS Soc. 2025 Feb; 28(2):e26422.
-
Characterizing HIV seroconversions among a cohort of oral PrEP users in South Africa. J Int AIDS Soc. 2025 Feb; 28(2):e26421.
-
Experiences with Oral Pre-Exposure Prophylaxis (PrEP) Service Delivery and Use Among Adolescent Girls and Young Women (AGYW) in Routine Primary Care Settings, South Africa. AIDS Behav. 2025 Apr; 29(4):1216-1227.
-
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084. J Int AIDS Soc. 2025 Jan; 28(1):e26401.